抑制CDK4/CDK6增强HPV阴性头颈部鳞癌的放射敏感性
该研究探讨CDK4/CDK6抑制剂帕博西利对HPV阴性和阳性头颈部鳞癌细胞系放射敏感性的影响。结果显示帕博西利仅使HPV阴性细胞放射增敏,且伴随BRCA1和RAD51诱导减少、同源重组减弱、DNA损伤修复延迟及染色体损伤增加。
要点
- 帕博西利仅对HPV阴性头颈部鳞癌细胞产生放射增敏作用
- 增敏机制涉及同源重组受损和DNA损伤修复延迟
- 为HPV阴性头颈部鳞癌放疗疗效提升提供潜在策略
核心结论
- 抑制CDK4/CDK6可增强HPV阴性头颈部鳞癌的放射敏感性,为这类预后较差的患者提供潜在治疗策略。
研究设计与样本
- 研究使用临床批准的CDK4/CDK6抑制剂帕博西利,在HPV阴性和HPV阳性头颈部鳞癌细胞系中评估放射增敏效果。
- 方法包括集落存活分析、修复蛋白免疫荧光染色、同源重组分析、细胞周期分析和中期染色体铺展分析。
主要发现
- 帕博西利仅使HPV阴性头颈部鳞癌细胞放射增敏,且在缺氧条件下也出现增敏。
- 帕博西利导致照射后BRCA1和RAD51诱导减少,同源重组减弱,辐射诱导DNA损伤修复延迟,染色体损伤增加。
- 修复失败导致细胞有丝分裂灾难而死亡。
临床怎么用
- 帕博西利可能作为HPV阴性头颈部鳞癌放疗的增敏剂,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Human papillomavirus negative (HPV-ve) head and neck squamous cell carcinoma (HNSCC) has a poor prognosis compared with HPV+ve HNSCCs. Expression of p16 in HPV+ve HNSCC is thought to mediate radiosensitivity via inhibition of cyclin-dependent kinase (CDK) 4/6. We used a clinically approved CDK4/CDK6 inhibitor, palbociclib, and assessed its effect on radiosensitivity in HNSCC. METHODS AND MATERIALS: The effect of palbociclib on radiosensitivity was determined in HPV-ve and HPV+ve HNSCC cell lines using colony survival assays, immunofluorescent staining of repair proteins, homologous recombination assays, cell cycle, and metaphase spread analyses. RESULTS: Only HPV-ve HNSCC cells were radiosensitized by palbociclib, which also occurred at hypoxic levels associated with radioresistance. Palbociclib led to decreased induction of BRCA1 and RAD51 after irradiation. Homologous recombination was diminished and repair of radiation-induced DNA damage was delayed in the presence of palbociclib, leading to increased chromosomal damage. Failure to repair radiation-induced damage led to cell death as a result of mitotic catastrophe. CONCLUSIONS: Here, we highlight a therapeutic strategy to improve the radiosensitivity of HPV-ve HNSCC, a patient group that has an unmet and urgent need for improved radiation therapy efficacy.
引用
- Göttgens EL, Bussink J, Leszczynska KB, et al. Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas. Int J Radiat Oncol Biol Phys. 2019. PMID: 31271827. doi:10.1016/j.ijrobp.2019.06.2531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。